NCT01441193View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
HIV Infection
Interventions
BIOLOGICAL

HIV-1 Tat/delta-V2 Env combined vaccine

BIOLOGICAL

HIV-1 delta-V2 Env vaccine

BIOLOGICAL

HIV-1 Tat vaccine 7.5 microg

BIOLOGICAL

HIV-1 Tat vaccine 30 microg

Trial Locations (3)

20052

Azienda Ospedaliera San Gerardo, Divisione di Malattie Infettive, Monza

41100

Policlinico di Modena, Divisione di Malattie Infettive, Modena

00153

IFO - S. Gallicano, Dermatologia Infettiva, Rome

Sponsors

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Barbara Ensoli, MD

OTHER